Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope
- PMID: 10201941
Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope
Abstract
Bordetella pertussis secretes an invasive adenylate cyclase toxin, CyaA, that is able to deliver its N-terminal catalytic domain into the cytosol of eukaryotic target cells directly through the cytoplasmic membrane. We have shown previously that recombinant CyaA can be used to deliver viral CD8+ T cell epitopes to the MHC-class I presentation pathway to trigger specific CTL responses in vivo. In the present study, we show that mice immunized with a detoxified but still invasive CyaA carrying a CD8+ T cell epitope of OVA developed strong epitope-specific CTL responses, which kill tumor cells expressing this Ag. Treating mice with this recombinant molecule after the graft of melanoma cells expressing OVA induced a strong survival advantage compared with control animals. To our knowledge, this study represents the first demonstration that a nonreplicative and nontoxic vector carrying a single CTL epitope can stimulate efficient protective and therapeutic antitumor immunity.
Similar articles
-
In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes.J Immunol. 1996 Jun 15;156(12):4697-706. J Immunol. 1996. PMID: 8648115
-
Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.Cancer Res. 2005 Jan 15;65(2):641-9. Cancer Res. 2005. PMID: 15695409
-
Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity.J Virol. 2001 Aug;75(16):7330-8. doi: 10.1128/JVI.75.16.7330-7338.2001. J Virol. 2001. PMID: 11462005 Free PMC article.
-
The adenylate cyclase toxin from Bordetella pertussis--a novel promising vehicle for antigen delivery to dendritic cells.Int J Med Microbiol. 2004 Apr;293(7-8):571-6. doi: 10.1078/1438-4221-00291. Int J Med Microbiol. 2004. PMID: 15149033 Review.
-
Adenylate cyclase toxin-hemolysin relevance for pertussis vaccines.Expert Rev Vaccines. 2014 Oct;13(10):1215-27. doi: 10.1586/14760584.2014.944900. Epub 2014 Aug 4. Expert Rev Vaccines. 2014. PMID: 25090574 Review.
Cited by
-
Targeting Dendritic Cells in vivo for Cancer Therapy.Front Immunol. 2012 Feb 7;3:13. doi: 10.3389/fimmu.2012.00013. eCollection 2012. Front Immunol. 2012. PMID: 22566899 Free PMC article.
-
Bordetella adenylate cyclase toxin: a unique combination of a pore-forming moiety with a cell-invading adenylate cyclase enzyme.Pathog Dis. 2015 Nov;73(8):ftv075. doi: 10.1093/femspd/ftv075. Epub 2015 Sep 20. Pathog Dis. 2015. PMID: 26391732 Free PMC article. Review.
-
High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.Infect Immun. 2006 Jun;74(6):3396-407. doi: 10.1128/IAI.02086-05. Infect Immun. 2006. PMID: 16714570 Free PMC article.
-
The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18).J Exp Med. 2001 May 7;193(9):1035-44. doi: 10.1084/jem.193.9.1035. J Exp Med. 2001. PMID: 11342588 Free PMC article.
-
Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis.Infect Immun. 2000 Jul;68(7):3867-72. doi: 10.1128/IAI.68.7.3867-3872.2000. Infect Immun. 2000. PMID: 10858196 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Research Materials